Leigh Syndrome Treatment Market Research Report -Forecast till 2027

Leigh Syndrome Treatment Market Research Report: By Diagnosis (MRI, CT, and Laboratory Test), By Treatment (Medications, Medical Procedure, and Surgery), By End User (Hospital, Research Organizations and Academic Institutes)- Forecast till 2027

ID: MRFR/HC/3811-HCR | | Region: Global | 90 Pages         

Leigh Syndrome Treatment Market Scenario

Leigh syndrome is a rare genetic disorder characterized by progressive damage to the central nervous system. This condition is caused due to defective functioning of mitochondria within the cells of the body. The symptoms are seen after birth which includes loss of head control and seizures. Various forms of leigh's disease have a poor prognosis. Most cases are fatal during childhood, although some individuals have reported surviving to adolescence. This progressive disorder begins in infants between the ages of three months to two years.

Leigh's disease can be caused by mutations in mitochondrial DNA or by deficiencies of an enzyme called pyruvate dehydrogenase. The risk of passing the abnormal gene from affected parent to offspring is 50 percent for each pregnancy. According to the United Mitochondrial Disease Foundation, the estimated incidence of Leigh’s disease is one in 77,000 births or one per 40,000 births for Leigh and Leigh-like disease. However, this may be an underestimate since mitochondrial diseases tend to be misdiagnosed. The disorders are due to a broad range of genetic mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA).

The most common treatment for Leigh's disease is thiamine or Vitamin B1. Oral sodium bicarbonate or sodium citrate may also be prescribed to manage lactic acidosis. Currently, dichloroacetate is being tested to establish its effectiveness in treating lactic acidosis. Leigh disease occurs in at least 1 of 40,000 live births, though certain populations have much higher rates.

The Global Leigh Syndrome Treatment Market is expected to grow at a CAGR of approximately 6.5% during the forecast period 2017-2023.


Research Methodology Leigh Syndrome Treatment Market

Sources: Annual reports, Press release, White paper, and Company presentation

Leigh Syndrome Treatment Market Key Players

The existing players are strengthening their foothold in the industry by introducing technologically advanced products. Some of key the players in the global leigh syndrome treatment market are GlaxoSmithKline Plc (GSK), Brother Enterprises (China), Huazhong Pharma (China), Zhejiang Tianxin (China),  Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Wright Medical Technology, Inc. (U.S.), Integra LifeSciences Holdings Corporation (U.S.), and others.

Leigh Syndrome Treatment Market Segmentation

The leigh syndrome treatment is segmented on the basis of diagnosis, treatment, and end-users.

On the basis of the diagnosis, the leigh syndrome treatment market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), laboratory test, and others. The laboratory test is divided into blood test, serum test, urine test, and others.

On the basis of the treatment, the market is segmented into medications, medical procedures, and surgery.

On the basis of the end-user, the market is segmented into the hospital, research organizations, and academic institutes.

Leigh Syndrome Treatment Market Regional Analysis

The global leigh syndrome treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The Americas is projected to hold the largest share of the global leigh syndrome treatment market due to the increasing mitochondrial disorders in the U.S. According to the National Center for Advancing Translational Science (NIH), Leigh syndrome is much more common in certain populations. For instance, the condition occurs in approximately 1 in 2,000 newborns in Quebec, Canada and approximately 1 in 1,700 in countries such as Norway and Iceland.

Europe is expected to capture the second lead in leigh syndrome treatment market in the coming five years owing to substantial technological advancements. The leigh syndrome treatment market in the Asia Pacific is expected to witness the fastest growth rate within the forecast period due to increasing birth rates coupled with increasing number of genetic disorders. The developing countries are facing a poor prognosis, with death usually occurring in childhood. The later the onset, the slower the deterioration. Death is most frequently due to respiratory failure. The Middle East and Africa leigh syndrome treatment market are also expected to show a healthy growth in the coming five years.

Intended Audience

  • Leigh Syndrome Devices Suppliers

  • Leigh Syndrome Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Speak to Analyst Ask for Customization